Evidence map›Paper›PMID 30768863›Full record

ArticleStem cells translational medicine2019

Human Fibrinogen for Maintenance and Differentiation of Induced Pluripotent Stem Cells in Two Dimensions and Three Dimensions.

Jarel K Gandhi, Travis Knudsen, Matthew Hill, Bhaskar Roy, Lori Bachman, Cynthia Pfannkoch-Andrews, Karina N Schmidt, Muriel M Metko, Michael J Ackerman, Zachary Resch and 2 more

Open access · goldAbstract read
In one paragraph

Article in Stem cells translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Detection of Residual iPSCs Following Differentiation of iPSC-Derived Retinal Pigment Epithelial Cells.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2024
    Article
  9. Article
  10. Matrices Activated with Messenger RNA.Journal of functional biomaterials · 2023
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Jarel K GandhiDepartment of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-7856-5608
Travis KnudsenDepartment of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA.
Matthew HillDepartment of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA.
Bhaskar RoyCenter for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Lori BachmanDepartment of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA.
Cynthia Pfannkoch-AndrewsDepartment of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA.
Karina N SchmidtDepartment of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA.
Muriel M MetkoDepartment of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA.
Michael J AckermanDepartments of Cardiovascular Medicine, Pediatric and Adolescent Medicine, and Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
Zachary ReschCenter for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Jose S PulidoDepartment of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA.
Alan D MarmorsteinDepartment of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA.
Mayo Clinic · USMayo Clinic in Arizona · USMayo Clinic in Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human fibrin hydrogels are a popular choice for use as a biomaterial within tissue engineered constructs because they are biocompatible, nonxenogenic, autologous use compatible, and biodegradable. We have recently demonstrated the ability to culture induced pluripotent stem cell (iPSC)-derived retinal pigment epithelium on fibrin hydrogels. However, iPSCs themselves have relatively few substrate options (e.g., laminin) for expansion in adherent cell culture for use in cell therapy. To address this, we investigated the potential of culturing iPSCs on fibrin hydrogels for three-dimensional applications and further examined the use of fibrinogen, the soluble precursor protein, as a coating substrate for traditional adherent cell culture. iPSCs successfully adhered to and proliferated on fibrin hydrogels. The two-dimensional culture with fibrinogen allows for immediate adaption of culture models to a nonxenogeneic model. Similarly, multiple commercially available iPSC lines adhered to and proliferated on fibrinogen coated surfaces. iPSCs cultured on fibrinogen expressed similar levels of the pluripotent stem cell markers SSea4 (98.7% ± 1.8%), Oct3/4 (97.3% ± 3.8%), TRA1-60 (92.2% ± 5.3%), and NANOG (96.0% ± 3.9%) compared with iPSCs on Geltrex. Using a trilineage differentiation assay, we found no difference in the ability of iPSCs grown on fibrinogen or Geltrex to differentiate to endoderm, mesoderm, or ectoderm. Finally, we demonstrated the ability to differentiate iPSCs to endothelial cells using only fibrinogen coated plates. On the basis of these data, we conclude that human fibrinogen provides a readily available and inexpensive alternative to laminin-based products for the growth, expansion, and differentiation of iPSCs for use in research and clinical cell therapy applications. Stem Cells Translational Medicine 2019;8:512-521.

Indexed as

Antigens, CDCadherin 5CadherinsCell Culture TechniquesCell DifferentiationEndothelial CellsFibrinFibrinogenHumansHydrogelsInduced Pluripotent Stem CellsNanog Homeobox ProteinOctamer Transcription Factor-3Antigens, CDCadherin 5CadherinsFibrinFibrinogenHydrogelsNanog Homeobox ProteinOctamer Transcription Factor-3Clinical translationEndothelial cellsInduced pluripotent stem cellsTissue engineering

Identifiers

PMID30768863
PMCPMC6525556
OpenAlexW2912446726

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.